Simona Skerjanec Increases Stake in IMUX with Recent Purchase
Simona Skerjanec acquired 25,370 shares of IMUX on June 29, joining a wave of insider buying.
Key Points
- Simona Skerjanec bought 25,370 shares of IMUX on June 29, 2026, as part of a series of insider purchases.
- Shares of IMUX traded near $15.30 on Tuesday, with several institutional investors adjusting their positions.
- Analysts from B. Riley Securities, HC Wainwright & Co., and others maintain a 'buy' rating on IMUX.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Simona Skerjanec recently purchased 25,370 shares of IMUX on June 29, 2026. This transaction is part of a larger trend of insider buying within the company, with several other insiders making significant purchases on the same day.
Insider Buying and Selling at Immunic, Inc.
On June 29, 2026, several insiders at IMUX made substantial share purchases. Jon Congleton acquired 50,740 shares, while Jason Tardio, President and COO, bought 253,000 shares. Chief Financial Officer Glenn Whaley purchased 120,000 shares. Joerg Neermann and Tamar Howson each added 25,370 shares to their holdings, and Daniel Vitt bought 445,000 shares. These transactions were not part of any pre-planned trading program.
Other Institutional Activity in IMUX
Several institutional investors have also adjusted their positions in IMUX. ABERDEEN GROUP PLC and BVF INC/IL both reduced their holdings by approximately 90%, ending with 824,394 and 765,297 shares, respectively. AVIDITY PARTNERS MANAGEMENT LP decreased its stake by 85.7%, holding 669,941 shares. In contrast, VANGUARD CAPITAL MANAGEMENT LLC and SOLEUS CAPITAL MANAGEMENT, L.P. opened new positions with 513,832 and 450,000 shares, respectively. SIMPLIFY ASSET MANAGEMENT INC. also initiated a stake with 438,932 shares.
Immunic, Inc. Stock Up 0.1%
Shares of IMUX traded near $15.30 on Tuesday. The stock has seen various institutional and insider activities recently, reflecting a dynamic market interest.
$IMUX stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts have been active in setting targets for IMUX. On May 22, 2026, B. Riley Securities maintained a 'buy' rating with a price target of $27. HC Wainwright & Co. also maintained a 'buy' rating with a target of $22 on April 30, 2026. Stifel initiated coverage with a 'buy' rating and a $2.50 target on April 17, 2026. The consensus among analysts remains positive, with multiple firms reiterating 'buy' ratings.
Bottom Line
Simona Skerjanec's recent purchase of IMUX shares highlights a broader trend of insider confidence in the company. Investors often monitor these insider activities for potential signals about a company's prospects. While the 13F filings and insider transactions provide a backward-looking view, they offer valuable insights into the sentiment within the company.
Get Immunic, Inc. alerts
New 13F filings, insider trades, and analyst moves on $IMUX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.